These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7851109)

  • 1. Is double data entry necessary? The CHART trials. CHART Steering Committee. Continuous, Hyperfractionated, Accelerated Radiotherapy.
    Gibson D; Harvey AJ; Everett V; Parmar MK
    Control Clin Trials; 1994 Dec; 15(6):482-8. PubMed ID: 7851109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee.
    Saunders MI; Dische S; Barrett A; Parmar MK; Harvey A; Gibson D
    Br J Cancer; 1996 Jun; 73(12):1455-62. PubMed ID: 8664112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Medical Research Council CHART Steering Committee.
    Coyle D; Drummond MF
    Clin Oncol (R Coll Radiol); 1997; 9(5):313-21. PubMed ID: 9368727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated [correction of acclerated] radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee.
    Bailey AJ; Parmar MK; Stephens RJ
    J Clin Oncol; 1998 Sep; 16(9):3082-93. PubMed ID: 9738579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee.
    Saunders M; Dische S; Barrett A; Harvey A; Gibson D; Parmar M
    Lancet; 1997 Jul; 350(9072):161-5. PubMed ID: 9250182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee.
    Saunders M; Dische S; Barrett A; Harvey A; Griffiths G; Palmar M
    Radiother Oncol; 1999 Aug; 52(2):137-48. PubMed ID: 10577699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee.
    Parmar MK; Spiegelhalter DJ; Freedman LS
    Stat Med; 1994 Jul 15-30; 13(13-14):1297-312. PubMed ID: 7973211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical and psychological symptoms of quality of life in the CHART randomized trial in head and neck cancer: short-term and long-term patient reported symptoms. CHART Steering Committee. Continuous hyperfractionated accelerated radiotherapy.
    Griffiths GO; Parmar MK; Bailey AJ
    Br J Cancer; 1999 Dec; 81(7):1196-205. PubMed ID: 10584882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with CHART.
    Saunders MI; Dische S; Grosch EJ; Fermont DC; Ashford RF; Maher EJ; Makepeace AR
    Int J Radiat Oncol Biol Phys; 1991 Aug; 21(3):871-8. PubMed ID: 1651312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer and CHART (continuous hyperfractionated accelerated radiotherapy)--where do we stand?
    Eakin RL; Saunders MI
    Ulster Med J; 2000 Nov; 69(2):128-36. PubMed ID: 11196724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions.
    Hatton MQ; Martin JE
    Clin Oncol (R Coll Radiol); 2010 Jun; 22(5):356-64. PubMed ID: 20399629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group.
    Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP
    Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Non-small Cell Lung Cancer (NSCLC): 7 Years' Experience From Nine UK Centres.
    Sanganalmath P; Lester JE; Bradshaw AG; Das T; Esler C; Roy AEF; Toy E; Lester JF; Button M; Wilson P; Comins C; Atherton P; Pickles R; Foweraker K; Walker GA; Keni M; Hatton MQ
    Clin Oncol (R Coll Radiol); 2018 Mar; 30(3):144-150. PubMed ID: 29336865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.
    De Ruysscher D; Wanders R; van Haren E; Hochstenbag M; Geraedts W; Pitz C; Simons J; Boersma L; Verschueren T; Minken A; Bentzen SM; Lambin P
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):132-8. PubMed ID: 18037581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer.
    Dobrowsky W; Naudé J; Widder J; Dobrowsky E; Millesi W; Pavelka R; Grasl C; Reichel M
    Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):803-6. PubMed ID: 9845100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course from first symptom to treatment in patients with non-small cell lung cancer referred for radiotherapy: a report by the CHART Steering Committee.
    Dische S; Gibson D; Parmar M; Saunders MI
    Thorax; 1996 Dec; 51(12):1262-5. PubMed ID: 8994526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine use of continuous, hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer: a five-center experience.
    Din OS; Lester J; Cameron A; Ironside J; Gee A; Falk S; Morgan SA; Worvill J; Hatton MQ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):716-22. PubMed ID: 18355975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
    Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus.
    Saunders MI; Dische S
    Int J Radiat Oncol Biol Phys; 1990 Nov; 19(5):1211-5. PubMed ID: 2174840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.